The X mnI and BCL11A Single Nucleotide Polymorphisms May Help Predict Hydroxyurea Response in Iranian β-Thalassemia Patients.

Autor: Banan, Mehdi, Bayat, Hadi, Azarkeivan, Azita, Mohammadparast, Saeid, Kamali, Koorosh, Farashi, Samaneh, Bayat, Nooshin, Khani, Masumeh Hadavand, Neishabury, Maryam, Najmabadi, Hossein
Předmět:
Zdroj: Hemoglobin; Aug2012, Vol. 36 Issue 4, p371-380, 10p
Abstrakt: Hydroxyurea (HU), a drug which can reactivate fetal hemoglobin (Hb F) production, is frequently prescribed to β-thalassemia (β-thal) patients. However, transfusion requirements of only a subset of patients are reduced upon HU treatment. Because of its potential side-effects, targeted prescription of HU is imperative. To identify genetic markers that correlate with drug response, we have carried out a retrospective association study of single nucleotide polymorphisms (SNPs) in three Hb F quantitative trait loci (QTLs): the XmnI polymorphism, BCL11A, and the HBS1L-MYB intergenic region, with the response to HU in a cohort of 81 transfusion-dependent Iranian β-thal patients. An increase in blood transfusion intervals post-therapy was used to measure drug response. Our results suggest that presence of the XmnI T/T genotype or the BCL11A rs766432 C allele correlates strongly with response to HU ( p <0.001). Accordingly, these markers may be used to accurately predict the HU response of Iranian β-thal patients. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje